Short answer
BioAge Labs, Inc. (BIOA) filed its Q3 2025 10-Q quarterly report on Nov 6, 2025 for the quarter ended Sep 30, 2025. Quarterly revenue was $2M with net income of −$20M.
Q3 2025 key financials · XBRL
- Revenue
- $2M
- −14.8% QoQ
- Net income
- −$20M
- +59.6% YoY · +6.5% QoQ
- Operating margin
- -1126.6%
- EPS (diluted)
- −$0.56
- +97.4% YoY · +6.7% QoQ
Source: XBRL data from the BioAge Labs, Inc. (BIOA) Q3 2025 10-Q on SEC EDGAR. USD.
BioAge Labs, Inc. Q3 2025 10-Q analysis
AI summary of MD&A and risk factor updates
Risk Factors
- Clinical and regulatory risk: BGE-102 and APJ programs still require FDA or foreign approvals before commercial sales
- Operational risk: Uncertainty of success in preclinical studies and clinical trials remains central to product development
- Competitive risk: Substitute products and larger companies may limit market acceptance
- Financial risk: Accumulated deficit reached $307.5 million as of September 30, 2025
- Liquidity risk: Cash, cash equivalents, and marketable securities totaled $295.9 million, including $10.1 million long-term marketable securities
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other BioAge Labs, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.